Oversight Explorer Logo

House Oversight Document Explorer

Search and explore committee documents

Documents tagged "Pricey Cholesterol"

Found 2 documents with this tag

HOUSE_OVERSIGHT_026362.txt

The FDA has approved Praluent, a new cholesterol-lowering medicine for people with established heart disease whose risk is not adequately controlled by existing statin drugs. It is administered through an injection and its long-term effects are unknown. The approval of this drug marks a significant advancement in the battle against heart disease, particularly for patients who have been difficult to treat due to high levels of LDL cholesterol. However, the new drug's cost may pose financial challenges down the line.

HOUSE_OVERSIGHT_025888.txt

This document discusses the FDA approval of a new cholesterol-lowering drug called Praluent, which is manufactured by Regeneron Pharmaceuticals. The article highlights the potential benefits and costs associated with this medication, as well as its impact on the battle against heart disease. Notable individuals mentioned in the document include Sultan Bin Sulayem, Jeffrey Epstein, Forbes Staff writer Matthew Herper, and Steven Nissen of the Cleveland Clinic.